Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[New thrombolytic agents].

G Nguyen, M Samama

    Annales De Biologie Clinique
    |January 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    New thrombolytic agents like tissue plasminogen activator (t-PA) and single-chain urokinase (scu-PA) offer effective clot-busting with reduced bleeding risks. Acyl enzymes also show promise but require further study for safety and efficacy in acute myocardial infarction.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Accuracy and reliability of an augmented reality prototype for robot-assisted partial nephrectomy: a preclinical study with 3D-printed kidney phantoms (UroCCR 168).

    Journal of robotic surgery·2026
    Same author

    SU-E-T-275: Dose Verification in a Small Animal Image-Guided Radiation Therapy X-Ray Machine: A Dose Comparison between TG-61 Based Look-Up Table and MOSFET Method for Various Collimator Sizes.

    Medical physics·2017
    Same author

    SU-D-217BCD-06: Evaluation of Effective Dose during Neuro 3-D Imaging Using a C-Arm Cone-Beam CT System.

    Medical physics·2017
    Same author

    Evaluation of the efficacy and tolerance of a short 7 day third-generation cephalosporin treatment in the management of acute pyelonephritis in young women in the emergency department.

    The Journal of antimicrobial chemotherapy·2016
    Same author

    Rectification properties of conically shaped nanopores: consequences of miniaturization.

    Physical chemistry chemical physics : PCCP·2013
    Same author

    Recommendations on biosimilar low-molecular-weight heparins.

    Journal of thrombosis and haemostasis : JTH·2009
    Same journal

    [The role of the heart-on-a-chip to drug evaluation].

    Annales de biologie clinique·2026
    Same journal

    A morphology-driven proof-of-concept study linking interphase nuclear abnormalities to dicentric-mediated genomic instability.

    Annales de biologie clinique·2026
    Same journal

    Analytical validation and clinical concordance of Diazyme free light chain assays on the Cobas® platform compared with Freelite™.

    Annales de biologie clinique·2026
    Same journal

    Small-cell secondary plasma cell leukemia mimicking low-grade B-cell lymphoma.

    Annales de biologie clinique·2026
    Same journal

    [Multiple myeloma and analytical discrepancy in serum free light chain assay: a case report].

    Annales de biologie clinique·2026
    Same journal

    [Summary of the 34th National Conference of the National College of Hospital Biochemistry].

    Annales de biologie clinique·2026
    See all related articles

    Area of Science:

    • Cardiovascular Medicine
    • Biochemistry
    • Pharmacology

    Context:

    • Acute myocardial infarction (AMI) treatment relies on effective thrombolysis.
    • Traditional thrombolytics like Streptokinase (SK) carry significant bleeding risks due to systemic fibrinogen degradation.
    • Novel fibrin-specific thrombolytic agents are being developed to improve safety profiles.

    Purpose:

    • To compare the efficacy and safety of new thrombolytic agents: tissue plasminogen activator (t-PA), single-chain urokinase (scu-PA), and acyl enzymes (APSAC).
    • To evaluate their fibrin affinity, thrombolytic activity, and impact on systemic fibrinolysis and bleeding risks.

    Summary:

    • Tissue Plasminogen Activator (t-PA) and Single Chain Urokinase Plasminogen Activator (scu-PA) are recombinant, fibrin-specific thrombolytics with high fibrin affinity and reduced systemic fibrinolytic effects.

    Related Experiment Videos

  • Acyl enzymes like APSAC offer a longer half-life and bolus administration but can cause severe fibrinogenolysis.
  • All three agents demonstrate comparable thrombolytic activity on coronary thrombi, but further research is needed.

    • Impact:

    • These agents offer potential for improved therapeutic outcomes in AMI by balancing effective clot lysis with minimized hemorrhagic complications.
    • Further clinical evaluation is crucial to determine optimal utilization, bleeding incidence, and reocclusion rates.
    • Advancements in thrombolytic therapy pave the way for safer and more effective treatments for thrombotic events.